MSH2 and glioblastoma: After TMZ treatment, MEX3A expression is increased in GBM cells, binding to MSH2 mRNA and recruiting the CCR4-NOT complex to facilitate its degradation. Consequently, this leads to reduced DNA mismatch repair activity and decreased sensitivity of GBM cells to TMZ.